Conference Proceedings

Years 6-10 (2007-2012)

  1. Cherrier M, Higano CS, Johnson M, Cross DJ, Minoshima S. Decreased cerebral metabolism from androgen suppression. IMPaCT: Innovative Minds in Prostate Cancer Today, Atlanta, GA, Sept 5-8, 2007.
  2. Cherrier MM, Green P, Schellenberg GS, Higano CS. Association of apolipoprotein E on serum abeta levels in men undergoing intermittent androgen ablation. Alzheimer’s Association International Conference on Alzheimer’s Disease, Chicago, IL. 2008
  3. Gulati R, Yu EY, Telesca D, Jiang P, Montgomery RB, Tam S, Russell KJ, Nelson PS, Etzioni RB, Higano CS. Testosterone kinetics in the first cycle of intermittent androgen deprivation for men with localized or biochemical relapse of prostate cancer. ASCO Annual Meeting, Chicago, IL. 2008
  4. Higano C, Saad F, Somer B, Curti B, Petrylak D, Drake CG, Schnell F, Redfern CH, Schrijvers D, Sacks N. A phase 3 trial of GVAX immunotherapy for prostate cancer vs. docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer. 2009 Genitourinary Cancers Symposium: A multidisciplinary approach, Orlando, FL, Feb 26-28, 2009.
  5. Higano CS, Alumkal J, Ryan CJ, Yu EY, Beer TM, Chandrawansa K, Katz T, Youssoufian H, Schwartz J, Prostate Cancer Clinical Trials Consortium. A phase 2 study evaluating the efficacy and safety of single agent IMC A12, a monoclonal antibody against the insulin-like growth factor-I receptor, as monotherapy in patients with metastatic, asymptomatic castrate resistant prostate cancer. 2009 ASCO Annual Meeting, Orlando, FL, May 29-June 2, 2009.
  6. Hotte SJ, Yu EY, Hirte HW, Higano CS, Gleave M, Chi KN. OGX-427, a 2’methoxyethyl antisense oligonucleotide against HSP27: results of a first-in human trial. 2009 ASCO Annual Meeting, Orlando, FL, May 29-June 2, 2009.
  7. Mostaghel EA, Montgomery RB, Vessella R, Kalhorn T, True L, Higano C, Nelson PS. Correlating androgen levels and steroidogenic enzyme expression in castration resistant prostate cancer metastases. ASCO Genitourinary Symposium, San Francisco, CA. 2008
  8. Rademacher BL, Garzotto M, Higano CS, O’Brien CA, Janeba N, Fazli L, Lange PH, Lieberman S, Beer TM. Five-year relapse-free survival and predictors of relapse following pre-operative docetaxel and mitoxantrone for high-risk localized prostate cancer. 2009 ASCO Annual Meeting, Orlando, FL, May 29-June 2, 2009.
  9. Rothenberg ML, Poplin E, Mehnert J, LoRusso P, Fox F, Schwartz J, Rowinsky E, Higano C. Pharmacokinetic and pharmacodynamic results of phase 1 studies of IMC-A12, a recombinant human insulin-like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid malignancies. 20th EORTC-NCI-AACR symposium on “Molecular targets and cancer therapeutics”, Geneva, Switzerland Oct 21-24, 2008.
  10. Schellhammer PF, Higano CS, Berger ER, Shore ND, Small EJ, Penson DF, Sims RB, Yuh L, Frohlich MW, Kantoff PW, for the IMPACT Study Investigators. A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma. 2009 ASCO Annual Meeting, Orlando, FL, May 29-June 2, 2009.
  11. Scher HI, Beer T, Higano CS, Efstathiou E, Shelky J, Hirmand M, Hung D, Anand A, Larson S, Fleisher Sawyers CL. Phase 1-2 study of MDV3100 in castration-resistant prostate cancer. Genitourinary Cancers Symposium: A multidisciplinary approach, Orlando, FL, Feb 26-28, 2009.
  12. Scher HI, Beer T, Higano C, Efstathiou E, Anand A, Hirmand M, Hung D, Larson S, Fleisher M, Sawyers C. Clinical study of MDV3100 in progressive castration-resistant prostate cancer. 2009 AUA Annual Meeting, Chicago, IL, April 25-30, 2009.
  13. Scher HI, Beer TM, Higano CS, Taplin M, Efstathiou E, Anand A, Hung D, Hirmand M, Fleisher M, The Prostate Cancer Clinical Trials Consortium. Anitumor activity of MDV3100 in a Phase 1-2 study of castration-resistant prostate cancer. 2009 ASCO Annual Meeting, Orlando, FL, May 29-June 2, 2009.
  14. Telesca D, Higano CS, Yu EY, Montgomery RB, Tam S, Russell KJ, Nelson PS, Etzioni RB. Duration of the first off treatment period is associated with time to androgen independence (AI) and survival in men with localized or biochemical relapse of prostate cancer treated on prospective trial of intermittent androgen deprivation (IAD). 2007 ASCO Annual Meeting, Chicago, IL. J Clin Oncol ASCO Annual Meeting Proceedings Part I. 25(18S):5146. 2007
  15. Wright JL, Lange PH, Ellis WJ, True LD, Lin DW. Clinicopathologic predictors of tertiary Gleason pattern 5 in radical prostatectomy specimens. 2008 American Urological Association, Orlando, FL. J Urol 179(4 suppl): 54-55. 2008
  16. Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, Hudes GR, Cheng S, Paliwal P, Sternberg CN. Dasatinib in patients with hormone-refractory progressive prostate cancer: a phase II study. Poster presentation at 2008 Prostate Cancer Foundation Scientific Symposium, Lake Tahoe, NV. October 16, 2008.
  17. Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, Hudes GR, Cheng S, Paliwal P, Sternberg CN. Dasatinib in patients with hormone-refractory progressive prostate cancer: a phase II study. Poster presentation at 2008 Prostate Cancer Foundation Scientific Symposium, Lake Tahoe, NV. October 16, 2008.